An abstract presenting the STHLM3 MR trial was awarded the “1st Prize Best Abstract Oncology 2021” at the annual European Association of Urology meeting. The trial included 12,750 men and concluded that combining the Stockholm3 test with MRI for prostate cancer screening decreases overdetection by 69 percent compared to Standard of Care, while maintaining detection of significant cancer.
In total, 4,000 abstracts were presented at the annual European Association of Urology, the largest scientific meeting in Europe within the field of Urology. The abstract “Risk-adapted screening with genomics and MRI: STHLM3 MR Phase 2 Trial” presented by Dr Tobias Nordström, Karolinska Institutet was awarded 1st Prize Best Abstract Oncology 2021.
The STHLM3 MR Trial is a randomized screen-by-invitation trial, comparing the standard test PSA with the Stockholm3 blood test when used with MRI-targeted or systematic biopsies for prostate cancer detection.
12,750 men in the age between 50 and 74 years participated in the trial. Compared to a screening strategy using PSA and systematic biopsies, Stockholm3 combined with MRI-targeted biopsies was associated with 69 percent fewer low-grade cancers and 53 percent fewer biopsy procedures.
“The results that Dr Nordström presented at EAU, in combination with our recently published paper in New England Journal of Medicine, provide evidence that the Stockholm3 test in combination with MRI provides a powerful and safe tool for prostate cancer screening. The significant reduction of overdetection and unnecessary procedures justifies introduction of general screening in men between the age of 50 and 74 to reduce their risk of dying of prostate cancer,” said Dr Henrik Grönberg, co-founder of A3P Biomedical and Professor of cancer epidemiology at Karolinska Institutet.
“These pivotal study results add to the significant body of data from studies of in total 80,000 men providing evidence of the value the Stockholm3 test. The healthcare providers in the Nordics that already transitioned to Stockholm3 are delivering outstanding results; 100 percent more aggressive cancers found, 50 percent reduction of unnecessary biopsies and 17 to 28 percent lower costs. A3P Biomedical is committed to making the Stockholm3 test available worldwide and look forward to work with our partners to improve men’s health and quality of life”, said David Rosen, CEO at A3P Biomedical.
For additional information, please contact:
David Rosen, CEO
telephone: +46 10 1823325
email: david.rosen@a3pbiomedical.com
Martin Steinberg, VP Corporate Development
telephone: +46 10 1823327
email: martin.steinberg@a3pbiomedical.com
About Stockholm3
Stockholm3 is a blood test that combines protein markers, genetic markers, clinical data, and a proprietary algorithm, to predict the risk of aggressive prostate cancer. Stockholm3 finds 100 percent more aggressive prostate cancers and reduces 50 percent of unnecessary biopsies compared to current practice with PSA (1).
Stockholm3 has been evaluated in clinical studies with more than 75,000 men. Data from a first pivotal study, including 58,000 men, was published in The Lancet Oncology in 2015 (1).
Based on robust peer-reviewed clinical data, leading Nordic healthcare providers such as Capio S:t Görans Hospital in Sweden and Stavanger University Hospital in Norway have replaced PSA with Stockholm3. Patients benefit from a more precise test (with increased sensitivity and specificity) and healthcare providers benefit from direct cost savings of 17 to 28 percent (1).
(1) Publications, results and clinical validation.
About prostate cancer
Prostate cancer is the second most common male cancer, and the fifth leading cause of cancer related death in men worldwide. In 2020, 1.4 million men were diagnosed with prostate cancer and 375,000 deaths were reported by GLOBOCAN. Incidence of prostate cancer is expected to increase by 70 percent until 2040, driven by an aging population.
About A3P Biomedical
A3P Biomedical’s mission is to improve quality of life of men by radically increasing the precision in prostate cancer diagnostics.
The company’s lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. Stockholm3 has been developed by scientists at Karolinska Institutet and validated in clinical studies including more than 75,000 men. A total of SEK 750 million has been invested in clinical research, product development and market validation activities of Stockholm3. A3P Biomedical is headquartered in Stockholm, Sweden.